bluebird bio stock (US0955031005): Delisting pending amid restructuring

bluebird bio faces delisting from Nasdaq pending stock liquidation, following a 1-20 reverse split in December 2024 and rebranding to Genetix Biotherapeutics in September 2025.

bluebird bio (NASDAQ:BLUE), now rebranded as Genetix Biotherapeutics, is facing delisting from Nasdaq pending stock liquidation, as noted in recent corporate action updates. This development comes after the company reported quarterly earnings on November 7, 2025, with EPS of ($13.20), beating consensus estimates of ($13.80), and revenue surging 17364.8% year-over-year, according to MarketBeat as of 05/14/2026. The stock last traded around $4.97, with a market cap of $48.67 million.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: bluebird bio, Inc.
• Sector/industry: Biotechnology / Gene therapies
• Headquarters/country: United States
• Core markets: Severe genetic diseases
• Key revenue drivers: Gene therapy commercialization
• Home exchange/listing venue: Nasdaq (BLUE)
• Trading currency: USD

bluebird bio: core business model

bluebird bio develops and commercializes gene therapies for severe genetic diseases and cancers. The company focuses on innovative treatments using lentiviral gene addition technology to address unmet medical needs, as described on its official website as of 05/14/2026. Originally founded in 1992, it went public in 2013, raising $89 million at $14-$16 per share.

Recent strategic shifts include a rebranding to Genetix Biotherapeutics announced on September 18, 2025, signaling a return to foundational roots in genetic medicines, per Yahoo Finance as of 09/18/2025. This move coincides with operational challenges reflected in financial metrics.

Main revenue and product drivers for bluebird bio

Revenue stems primarily from gene therapy products targeting conditions like beta-thalassemia, sickle cell disease, and cerebral adrenoleukodystrophy. In Q3 2025 results published November 7, 2025, revenue jumped dramatically due to base effects, though absolute figures remain modest at $103.95 million annually, with net margins at -565.74%, according to MarketBeat as of 05/14/2026.

Key drivers include approved therapies like Zynteglo and Skysona, though commercialization hurdles persist amid high R&D costs and cash burn. The company's employee count stands at 520, with a debt-to-equity ratio of 0.37.

Why bluebird bio matters for US investors

As a Nasdaq-listed biotech with therapies approved by the FDA, bluebird bio offers US investors exposure to cutting-edge gene therapy innovations amid a market where such stocks can drive sector gains. Its low market cap of $48.67 million positions it as a high-risk, high-reward play in the US biotech landscape.

Conclusion

bluebird bio's path through rebranding, earnings beats, a reverse split, and now potential delisting highlights the volatility in biotech investing. While revenue growth shows commercialization progress, persistent losses and liquidity issues pose challenges. US investors tracking gene therapy should monitor updates closely for impacts on Nasdaq exposure.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.